# US 11,304,942 B2 · Parenteral unit dosage form of dihydroergotamine > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 11,304,942 B2 - Document ID: US11304942B2 - Status: Granted - Kind: B2 - Application number: 16/705,435 - Filed: 2019-12-06 - Published: 2020-04-09 - Granted: 2022-04-19 - Earliest claimed: 2018-08-27 - Assignees: Sun Pharmaceutical Industries Limited - Applicants: Sun Pharmaceutical Industries Limited - Inventors: Alpesh Goyani; Deepak Singodia; Bhaskar Pallerla; Sudeep Kumar Agrawal; Subhas Balaram Bhowmick; Rajamannar Thennati - Web page: https://patentgrep.com/patent/US11304942B2 ## CPC - A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine - A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems - A61M 5/20: Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically (A61M5/142 takes precedence) - A61P 25/06: Antimigraine agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)} - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months. ## Claims ### Claim 1 A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or a pharmaceutically acceptable salt thereof as a sole active ingredient, and one or more pH adjusting agents, wherein the pH of the aqueous solution is in the range of 4.1 to 4.9, the solution is contained in an auto-injector or a prefilled syringe, the solution does not require reconstitution or dilution prior to subcutaneous administration, and said parenteral unit dosage form contains a substantially lower amount of an impurity of Formula I and an impurity of Formula II when compared to an aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months ### Claim 2 (depends on 1) The parenteral unit dosage form according to claim 1, wherein the pH of the aqueous solution is in the range of 4.2 to 4.8. ### Claim 3 (depends on 1) The parenteral unit dosage form according to claim 1, wherein the aqueous solution is free of preservative or complexing agent. ### Claim 4 (depends on 1) The parenteral unit dosage form according to claim 1, wherein the pharmaceutical acceptable salt of dihydroergotamine is dihydroergotamine mesylate and it is present at a concentration ranging from 0.5 to 1.5 mg/ml. ### Claim 5 (depends on 1) The parenteral unit dosage form according to claim 1, further comprising one or more co-solvents. ### Claim 6 (depends on 1) The parenteral unit dosage form of claim 1, wherein the dosage form is stored at 25° C. and 60% relative humidity for at least three months under an atmosphere containing less than 1% oxygen. ### Claim 7 (depends on 1) An auto-injector or a prefilled syringe comprising the parenteral dosage form of claim 1. ### Claim 8 (depends on 7) The auto-injector or prefilled syringe of claim 7, wherein the dosage form is covered with an overwrap pouch. ### Claim 9 A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or a pharmaceutically acceptable salt thereof as a sole active ingredient, and one or more pH adjusting agents, wherein the pH of the aqueous solution is in the range of 4.1 to 4.9, and wherein said parenteral unit dosage form contains a substantially lower amount of an impurity of Formula I when compared to an aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months. ### Claim 10 A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or a pharmaceutically acceptable salt thereof as a sole active ingredient, and one or more pH adjusting agents, wherein the pH of the aqueous solution is in the range of 4.1 to 4.9, and wherein said parenteral unit dosage form contains a substantially lower amount of an impurity of Formula II when compared to an aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months under an atmosphere containing less than 1% oxygen. ### Claim 11 A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or a pharmaceutically acceptable salt thereof as a sole active ingredient, and one or more pH adjusting agents, wherein the pH of the aqueous solution is in the range of 4.1 to 4.9, and wherein said parenteral unit dosage form contains a substantially lower amount of an impurity of Formula II when compared to an aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months in the presence of an oxygen scavenger.